2.7.3 Patients with Cancer-Related Pain and Patients in Palliative Care
Cancer pain affects millions of Americans.306,354 In addition, there are more than 14 million cancer survivors in the United States as a result of remarkable advances in cancer diagnosis and therapy. An estimated 40% of cancer survivors continue to experience persistent pain as a result of treatments such as surgery, chemotherapy, and radiation therapy.
Persistent pain is also common and significant in patients with a limited prognosis, as often encountered in hospice and palliative care environments.355
GAPS AND RECOMMENDATIONS
GAP 1: These patient populations are frequently managed by practitioners who do not specialize in pain or palliative care. Many oncologists and primary care physicians are not trained to recognize or treat persistent pain associated with cancer or other chronic medical problems with limited prognosis.
• RECOMMENDATION 1A: Clinicians should assess and address pain at each patient encounter. Causes of pain such as recurrent disease, second malignancy, or late-onset treatment effects should be evaluated, treated, and monitored.
GAP 2: Patients with persistent pain associated with cancer and/or cancer treatment or other chronic medical problems with limited prognosis in palliative care often receive less optimal care with restricted treatment modalities.
• RECOMMENDATION 2A: When clinically indicated, use multimodal and multidisciplinary treatment as part of cancer-related pain management and palliative care.
Cannabis and Cancer Pain
The welcome remarks are not accredited for continuing education.
Breaks are not accredited for continuing education.
Rocco, A. G., Palombi, D., & Raeke, D. (1995). Anatomy of the lumbar sympathetic chain. Regional Anesthesia and Pain Medicine, 20(1), 13-19.
Networking Lunches are not accredited for continuing education.
Breaks are not accredited for continuing education.
1. Explore algorithmic evidenced based approach to cancer pain management
2. Evaluate evidence for neuromodulation treatment options for cancer pain management
3. Assess gaps and barriers for adoption of neuromodulation therapies in cancer pain management.
Stearns, L. M., Abd-Elsayed, A., Perruchoud, C., Spencer, R., Hammond, K., Stromberg, K., & Weaver, T. (2020). Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesthesia and analgesia, 130(2), 289.
Receptions are not accredited for continuing education.
Open to all In-Person Attendees
The welcome remarks are not accredited for continuing education.
Breaks and Q&A are not accredited for continuing education.
Breaks and Q&A are not accredited for continuing education.
Breaks and Q&A are not accredited for continuing education.
This session is not provided for CME credits.
This session is not provided for CME credits.
This session is not provided for CME credits.